Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 32 clinical trials
featured
Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

The purpose of this study is to determine whether FT218 is safe and effective for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy.

excessive daytime sleepiness
somnolence
stimulant
cataplexy
multiple sleep latency test
  • 80 views
  • 10 Jul, 2018
  • 53 locations
featured
Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

The purpose of this study is to determine whether Sodium Oxybate is safe and effective for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy.  

excessive daytime sleepiness
sodium oxybate
stimulant
cataplexy
  • 217 views
  • 22 Feb, 2019
  • 1 location
featured
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN G3031 Compared to Placebo in Patients with Narcolepsy with and without Cataplexy

This is a study to evaluate how safe and effective an investigational medication (SUVN-G3031) is compared to placebo at reducing the excessive daytime sleepiness in patients with narcolepsy with

excessive daytime sleepiness
cataplexy
  • 184 views
  • 27 Jan, 2020
  • 1 location
Sodium Oxybate in Idiopathic Hypersomnia

this study evaluates of the efficacy of sodium oxybate on excessive daytime sleepiness using Epworth sleepiness scale over 8 weeks compared to placebo

excessive daytime sleepiness
sleepiness
multiple sleep latency test
xyrem
sodium oxybate oral solution
  • 45 views
  • 19 Feb, 2021
  • 1 location
A Wearable Morning Light Treatment for Postpartum Depression

depression symptoms, excessive daytime sleepiness, maternal-infant bonding, social functioning, and sleep-related impairment from pre- to post-treatment.

psychotherapy
seizures
scid
depressive symptoms
structured clinical interview
  • 2 views
  • 07 Jul, 2021
  • 1 location
TElemedicine for NARcolepsy

, metabolic, and psychosocial assessment. Primary (i.e., excessive daytime sleepiness according to the Epworth Sleepiness Scale) and secondary endpoints (i.e., other symptoms, metabolic control, quality of

  • 0 views
  • 26 Jan, 2021
  • 1 location
Validation of Sleep Healthcare System

excessive daytime sleepiness (EDS) or polysomnographic parameters were identified. Among those metabolites, L-Kynurenine and g-Glutamylleucine were metabolites associated with EDS which generated the AUROC

  • 0 views
  • 23 Jan, 2021
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with Myotonic Dystrophy

myotonic dystrophy
drug test
  • 0 views
  • 30 Aug, 2021
  • 7 locations
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study

The purpose of study JZP110-405 is to determine whether solriamfetol is effective at improving cognitive function in participants with excessive daytime sleepiness (EDS) associated with

  • 0 views
  • 15 Sep, 2021
  • 14 locations
A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome Followed by an Open Label Extension

The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with Prader Willi

antipsychotics
metformin
  • 0 views
  • 09 Sep, 2021
  • 13 locations